$682.1 M

ZIOP Mkt cap, 10-Jun-2019
ZIOPHARM Oncology Net income (Q2, 2019)-14.6 M
ZIOPHARM Oncology EBIT (Q2, 2019)-14.8 M
ZIOPHARM Oncology Cash, 30-Jun-201943.6 M

ZIOPHARM Oncology Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

800.0k1.4m4.3m6.9m

Revenue growth, %

72%216%58%

R&D expense

42.9m106.8m157.8m45.1m34.1m

General and administrative expense

15.7m17.6m14.4m14.8m19.9m

Operating expense total

58.5m124.4m172.2m59.9m54.1m

EBIT

(57.7m)(43.5m)(120.1m)(165.3m)(53.5m)(53.9m)

EBIT margin, %

(7214%)(3168%)(2772%)(2409%)

Net Income

(57.1m)(31.8m)(120.1m)(165.3m)(54.3m)(53.1m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

R&D expense

12.0m10.8m11.1m10.2m7.5m8.3m9.5m10.0m

General and administrative expense

3.1m3.4m3.0m2.8m4.3m7.1m3.1m3.8m3.7m3.5m3.6m3.8m3.6m6.2m4.9m4.3m4.1m4.8m

Operating expense total

9.3m10.0m11.4m12.6m78.5m14.5m20.0m14.0m132.9m12.5m15.6m14.6m14.7m16.3m12.4m12.6m13.6m14.8m

EBIT

(9.1m)(9.8m)(11.2m)(11.9m)(78.2m)(14.2m)(18.2m)(12.0m)(131.2m)(10.9m)(14.0m)(13.0m)(13.1m)(16.2m)(12.4m)(12.6m)(13.6m)(14.8m)

Net Income

(16.7m)(9.7m)(5.6m)(6.1m)(78.2m)(14.2m)(18.2m)(12.0m)(131.2m)(10.9m)(15.5m)(12.9m)(12.7m)(16.0m)(12.0m)(12.6m)(13.4m)(14.6m)

ZIOPHARM Oncology Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

68.2m42.8m140.7m81.1m70.9m61.7m

Accounts Receivable

145.0k446.0k508.4m19.0k1.9m

Inventories

1.9m1.1m11.4m23.8m

Current Assets

70.3m44.1m152.5m104.9m90.8m84.3m

PP&E

801.0k531.0k581.0k843.0k1.2m1.1m

Total Assets

71.8m45.2m153.7m106.3m105.6m95.1m

Accounts Payable

422.0k2.0m2.0m156.0k4.4m707.0k

Short-term debt

Current Liabilities

7.8m10.8m18.1m15.8m20.9m9.5m

Long-term debt

Total Debt

Total Liabilities

22.4m66.4m58.3m58.4m9.5m

Additional Paid-in Capital

651.7m

Retained Earnings

(372.6m)(492.7m)(658.0m)(712.4m)(566.3m)

Total Equity

49.4m33.8m87.4m(77.3m)(96.8m)85.6m

Financial Leverage

1.5 x1.3 x1.8 x-1.4 x-1.1 x1.1 x

ZIOPHARM Oncology Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(57.1m)(31.8m)(120.1m)(165.3m)(54.3m)(53.1m)

Depreciation and Amortization

738.0k462.0k357.0k290.0k369.0k575.0k

Accounts Receivable

(87.0k)(301.0k)425.0k2.0k(1.8m)

Inventories

5.0m809.0k(10.0m)(12.0m)

Accounts Payable

(1.1m)1.6m4.0k(1.9m)4.3m(3.7m)

Cash From Operating Activities

(59.5m)(36.6m)(10.0k)(58.3m)(54.7m)(49.5m)

Purchases of PP&E

(132.0k)(193.0k)(412.0k)(551.0k)(737.0k)(459.0k)

Cash From Investing Activities

(131.0k)(193.0k)(412.0k)(551.0k)(737.0k)(459.0k)

Cash From Financing Activities

54.5m11.4m98.3m(788.0k)45.3m40.3m

Interest Paid

Income Taxes Paid

ZIOPHARM Oncology Ratios

USDY, 2019

Financial Leverage

1.2 x